1
|
Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 2014; 24:283-307. [PMID: 25345753 DOI: 10.1517/13543784.2015.974804] [Citation(s) in RCA: 177] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes (T2DM) and cardiovascular disease (CVD). These observations suggest that pharmacological strategies, which reduce inflammation, may be therapeutically useful in treating obesity, type 2 diabetes and associated CVD. AREA COVERED The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-α (etanercept, infliximab, adalimumab), IL-1β (anakinra, canakinumab) and IL-6 (tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists. EXPERT OPINION The available data supports the concept that targeting inflammation improves insulin sensitivity and β-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity.
Collapse
Affiliation(s)
- Nathalie Esser
- University of Liege and Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Virology and Immunology Unit, GIGA-ST , CHU Liège, Liège , Belgium
| | | | | |
Collapse
|
2
|
Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems. Biochim Biophys Acta Mol Cell Biol Lipids 2013; 1831:1124-33. [PMID: 23545567 DOI: 10.1016/j.bbalip.2013.03.007] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 03/18/2013] [Accepted: 03/20/2013] [Indexed: 12/14/2022]
Abstract
The incidence of diseases characterized by a dysregulation of lipid metabolism such as obesity, diabetes and atherosclerosis is rising at alarming rates, driving research to uncover new therapies to manage dyslipidemias and resolve the metabolic syndrome conundrum. Autophagy and lipid homeostasis - both ancient cellular pathways - have seemingly co-evolved to share common regulatory elements, and autophagy has emerged as a prominent mechanism involved in the regulation of lipid metabolism. This review highlights recent findings on the role of autophagy in the regulation of cellular cholesterol homeostasis and lipoprotein metabolism, with special emphasis on macrophages. From modulation of inflammation to regulation of cellular cholesterol levels, a protective role for autophagy in atherosclerosis is emerging. The manipulation of autophagic activity represents a new possible therapeutic approach for the treatment complex metabolic disorders such as obesity and the metabolic syndrome.
Collapse
Affiliation(s)
- Mireille Ouimet
- Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
| |
Collapse
|
3
|
Martinet W, De Meyer I, Verheye S, Schrijvers DM, Timmermans JP, De Meyer GRY. Drug-induced macrophage autophagy in atherosclerosis: for better or worse? Basic Res Cardiol 2012; 108:321. [PMID: 23233268 DOI: 10.1007/s00395-012-0321-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2012] [Revised: 12/04/2012] [Accepted: 12/04/2012] [Indexed: 12/15/2022]
Abstract
Autophagy is a reparative, life-sustaining process by which cytoplasmic components are sequestered in double membrane vesicles and degraded upon fusion with lysosomal compartments. Mice with a macrophage-specific deletion of the essential autophagy gene Atg5 develop plaques with increased apoptosis and oxidative stress as well as enhanced plaque necrosis. This finding indicates that basal autophagy in macrophages is anti-apoptotic and present in atherosclerotic plaques to protect macrophages against various atherogenic stressors. However, autophagy is impaired in advanced stages of atherosclerosis and its deficiency promotes atherosclerosis in part through activation of the inflammasome. Because basal autophagy can be intensified selectively in macrophages by specific drugs such as mammalian target of rapamycin (mTOR) inhibitors or Toll-like receptor 7 (TLR7) ligands, these drugs were recently tested as potential plaque stabilizing compounds. Stent-based delivery of the mTOR inhibitor everolimus promotes a stable plaque phenotype, whereas local administration of the TLR7 ligand imiquimod stimulates inflammation and plaque progression. Therefore, more drugs capable of inducing autophagy should be tested in plaque macrophages to evaluate the feasibility of this approach. Given that drug-induced macrophage autophagy is associated with pro-inflammatory responses due to cytokine release, induction of postautophagic necrosis or activation of phagocytes after clearance of the autophagic corpse, cotreatment with anti-inflammatory compounds may be required. Overall, this review highlights the pros and cons of macrophage autophagy as a drug target for plaque stabilization.
Collapse
Affiliation(s)
- Wim Martinet
- Laboratory of Physiopharmacology, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium.
| | | | | | | | | | | |
Collapse
|
5
|
Martinet W, Verheye S, De Meyer I, Timmermans JP, Schrijvers DM, Van Brussel I, Bult H, De Meyer GR. Everolimus Triggers Cytokine Release by Macrophages. Arterioscler Thromb Vasc Biol 2012; 32:1228-35. [DOI: 10.1161/atvbaha.112.245381] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Objective—
Stent-based delivery of the mammalian target of rapamycin (mTOR) inhibitor everolimus is a promising strategy for the treatment of coronary artery disease. We studied potential adverse effects associated with mTOR inhibition.
Methods and Results—
Macrophages in culture were either treated with everolimus or starved to inhibit mTOR. Everolimus led to inhibition of protein translation, activation of p38 MAPK, and the release of proinflammatory cytokines (eg, IL-6, TNFα) and chemokines (eg, MCP1, Rantes) before induction of autophagic death. These effects were also observed with rapamycin, but not after starvation. Everolimus-induced cytokine release was similar in macrophages lacking the essential autophagy gene Atg7 but was inhibited when macrophages were cotreated with p38 MAPK inhibitor SB202190 or the glucocorticoid clobetasol. Combined stent-based delivery of clobetasol and everolimus in rabbit plaques downregulated TNFα expression as compared with everolimus-treated plaques but did not affect the ability of everolimus to induce macrophage clearance.
Conclusion—
mTOR inhibition by everolimus triggers cytokine release in macrophages through inhibition of protein translation and p38 activation. These findings provide a rationale for combined local treatment of atherosclerotic plaques with everolimus and an anti-inflammatory agent.
Collapse
Affiliation(s)
- Wim Martinet
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Stefan Verheye
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Inge De Meyer
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Jean-Pierre Timmermans
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Dorien M. Schrijvers
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Ilse Van Brussel
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Hidde Bult
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| | - Guido R.Y. De Meyer
- From the Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium (W.M., I.D.M., D.M.S., I.V.B., H.B., G.R.Y.D.M.); Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium (S.V.); and the Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium (J.-P.T.)
| |
Collapse
|
6
|
Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 2011; 13:655-67. [PMID: 21641547 PMCID: PMC3257518 DOI: 10.1016/j.cmet.2011.03.023] [Citation(s) in RCA: 554] [Impact Index Per Article: 42.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Revised: 01/24/2011] [Accepted: 03/23/2011] [Indexed: 12/20/2022]
Abstract
The lipid droplet (LD) is the major site of cholesterol storage in macrophage foam cells and is a potential therapeutic target for the treatment of atherosclerosis. Cholesterol, stored as cholesteryl esters (CEs), is liberated from this organelle and delivered to cholesterol acceptors. The current paradigm attributes all cytoplasmic CE hydrolysis to the action of neutral CE hydrolases. Here, we demonstrate an important role for lysosomes in LD CE hydrolysis in cholesterol-loaded macrophages, in addition to that mediated by neutral hydrolases. Furthermore, we demonstrate that LDs are delivered to lysosomes via autophagy, where lysosomal acid lipase (LAL) acts to hydrolyze LD CE to generate free cholesterol mainly for ABCA1-dependent efflux; this process is specifically induced upon macrophage cholesterol loading. We conclude that, in macrophage foam cells, lysosomal hydrolysis contributes to the mobilization of LD-associated cholesterol for reverse cholesterol transport.
Collapse
Affiliation(s)
- Mireille Ouimet
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
| | | | | | | | | | | |
Collapse
|